34,690 Shares in Stevanato Group S.p.A. (NYSE:STVN) Acquired by Allianz SE

Allianz SE bought a new stake in Stevanato Group S.p.A. (NYSE:STVN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 34,690 shares of the company’s stock, valued at approximately $748,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Conestoga Capital Advisors LLC grew its stake in shares of Stevanato Group by 5.3% during the fourth quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company’s stock worth $176,128,000 after purchasing an additional 407,086 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Stevanato Group by 114.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock valued at $71,657,000 after acquiring an additional 1,756,100 shares during the period. Wellington Management Group LLP raised its stake in shares of Stevanato Group by 4.5% during the third quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock worth $53,872,000 after purchasing an additional 115,050 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Stevanato Group by 28.7% in the 4th quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company’s stock worth $51,333,000 after acquiring an additional 524,989 shares during the period. Finally, Bamco Inc. NY lifted its position in Stevanato Group by 1.3% in the third quarter. Bamco Inc. NY now owns 1,685,181 shares of the company’s stock valued at $33,704,000 after purchasing an additional 21,469 shares during the period.

Analysts Set New Price Targets

A number of analysts recently commented on STVN shares. Bank of America boosted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. UBS Group reduced their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a report on Friday, March 7th. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Finally, Wolfe Research began coverage on Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Stevanato Group presently has a consensus rating of “Moderate Buy” and a consensus price target of €25.70 ($27.93).

Stevanato Group Stock Down 0.3 %

Shares of STVN stock opened at €20.25 ($22.01) on Monday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The business’s fifty day moving average is €20.90 and its 200-day moving average is €20.60. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.00) and a 1 year high of €32.98 ($35.85). The stock has a market cap of $6.13 billion, a PE ratio of 43.09, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting the consensus estimate of €0.20 ($0.22). The business had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Equities analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.